C of A [GxP / QC / QA]

posted by Dr_Dan  – Germany, 2011-02-16 12:00 (5599 d 11:56 ago) – Posting: # 6634
Views: 8,987

Dear Ohlbe

❝ Giving subjects a drug which has not been analysed or properly identified is of concern.


I guess the (reference) drug was purchased from the local market, right? So the originator analysed the product (batch) in order to release it. Every physician prescribing this product has to rely on this procedural step and by this on the quality. Since this is a registrated and marketed product I can see no ethical concern as long as the product is not manipulated before administration.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
141 visitors (0 registered, 141 guests [including 14 identified bots]).
Forum time: 00:56 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5